Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07277660 · ClinicalTrials.gov registry record · Phase 2
A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis
A Phase 2 study of Atopic Dermatitis, sponsored by UCB Biopharma SRL.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 160
- Enrollment target
- 20
- Study locations
NCT07277660 is a Phase 2 study of Atopic Dermatitis that is actively recruiting participants, run by UCB Biopharma SRL. The registered enrollment target is 160 participants, below the 608-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (74% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT07277660, a Phase 2 study of Atopic Dermatitis, is actively recruiting participants, sponsored by UCB Biopharma SRL.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 160 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to evaluate the dose-response relationship of galvokimig compared with placebo in study participants with moderate-to-severe atopic dermatitis (AtD).
Conditions Studied
Interventions
- DRUG Placebo
- BIOLOGICAL Galvokimig
Study Locations (20)
Texas
- Atd002 52005 - Dallas
- Atd002 52016 - Frisco
- Atd002 52011 - Frisco
- Atd002 52004 - Sugar Land
Florida
- Atd002 52013 - Boca Raton
- Atd002 52007 - Coral Gables
- Atd002 52003 - Miami
Other
- Atd002 51007 - Toronto
- Atd002 21005 - Sakai
- Atd002 21008 - Sapporo
Michigan
- Atd002 52001 - Troy
- Atd002 52009 - Troy
California
- Atd002 52008 - Santa Monica
Georgia
- Atd002 52015 - Savannah
Illinois
- Atd002 52018 - Wheaton
Indiana
- Atd002 52012 - New Albany
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2025-12-29 |
| Est. Completion | 2028-03-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07277660
The ClinicalTrials.gov registry entry for NCT07277660 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (74% lower). The listed sponsor is UCB Biopharma SRL, which has 82 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Atopic Dermatitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07277660 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Texas, Florida, Other.
Frequently Asked Questions
What is clinical trial NCT07277660 about?
NCT07277660 is a clinical study titled "A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis". The purpose of the study is to evaluate the dose-response relationship of galvokimig compared with placebo in study participants with moderate-to-severe atopic dermatitis (AtD).
What is the current status of trial NCT07277660?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 160 participants. The study started on 2025-12-29. Estimated completion is 2028-03-06.
What conditions does trial NCT07277660 study?
This clinical trial studies the following conditions: Atopic Dermatitis.
What interventions are being tested in trial NCT07277660?
The interventions under investigation include: Placebo (DRUG), Galvokimig (BIOLOGICAL).
Who is sponsoring clinical trial NCT07277660?
This trial is sponsored by UCB Biopharma SRL, which has 82 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07277660 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Cardamom and Topical Roseomonas in Atopic Dermatitis
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
A Study Evaluating TRIV-509 in Atopic Dermatitis
RECRUITING · Phase 2
-
A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.